摘要
目的:研究甲氨蝶呤联合复方倍他米松关节腔内注射在类风湿关节炎治疗中的临床应用价值。方法:2007年10月～2010年10月,我院纳入类风湿关节炎病例98例,按随机原则将所有观察对象分为治疗组和对照组,每组各49例。治疗组采用关节腔注入甲氨蝶呤10 mg/周,复方倍他米松7 mg/d;对照组采用关节腔注入甲氨蝶呤10 mg/周,小剂量(≤10 mg/d)强的松。观察治疗前后患者的关节肿胀数、压痛数、血沉(ESR)、C-反应蛋白(CRP)及类风湿因子(RF)的变化,并比较两组治疗的总有效率。结果:治疗组关节肿胀、压痛减少数多于对照组(P<0.05),治疗组ESR、CRP、RF改善情况显著优于对照组(P<0.01)。同时,治疗组总有效率优于对照组(P<0.05)。治疗组总不良反应发生2例(4.1%),对照组不良反应发生6例(12.2%),对照组不良反应发生率高于治疗组(P<0.05)。结论:甲氨蝶呤联合复方倍他米松关节腔内注射应用与类风湿关节炎治疗,具有高效、安全、不良反应少、耐受性佳等优势,可显著改善患者临床症状及预后情况,可作为类风湿关节炎的优选治疗方法。
Objective： To investigate the clinical significance of intra-articular injecting Methotrexate and Compound Betamethasone in treating rheumatoid arthritis.Methods： 98 patients with rheumatoid arthritis definitely diagnosed in our hospital from October 2007 to October 2010 were selected.They were divided into treatment group and control group randomly,each 49 cases.The treatment group was treated with Methotrexate 10 mg/w,and Compound Betamethasone 7 mg/d,while the control group was treated with Methotrexate 10 mg/w,and low dose（≤10 mg/d） Prednisone.Their quantity of swelling joint and joint with tenderness,CRP,ESR,RF were observed,and total efficiency of the two groups were compared.Results： The reducing quantity of swelling joint and joint with tenderness,CRP,ESR,RF and the total efficiency of treatment group were significantly higher than those of the control group（P〈0.05 or P〈0.01）.The incidence of adverse reactions of the treatment group（4.1%） was significantly lower than that of the control group（12.2%）（P〈0.05）.Conclusion：Intra-articular injecting Methotrexate and Compound Betamethasone shows obvious advantages in efficacy,safety,adverse reaction and tolerance.Thus it can be recognized as a prior choice in treating rheumatoid arthritis.
出处
《中国医药导报》
CAS
2011年第28期42-43,共2页
China Medical Herald
关键词
甲氨蝶呤
复方倍他米松
关节腔内注射
类风湿关节炎
Methotrexate
Compound Betamethasone
Intra-articular injection
Rheumatoid arthritis
